Functional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapse

Molecular Therapy

Volumn 21, Issue 8, 2013, Pages 1507-1516

  Boisgerault, Nicolas ^a   Kottke, Timothy ^a   Pulido, Jose ^a   Thompson, Jill ^a   Diaz, Rosa Maria ^a   Rommelfanger Konkol, Diana ^a   Embry, Addie ^a   Saenz, Dyana ^a   Poeschla, Eric ^a   Pandha, Hardev ^b   Harrington, Kevin ^c   Melcher, Alan ^d   Selby, Peter ^d   Vile, Richard ^a,d  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF SURREY   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE II ALPHA; DOXORUBICIN; GAMMA INTERFERON; INTERLEUKIN 17; PACLITAXEL; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG SENSITIVITY; DRUG TARGETING; GENE OVEREXPRESSION; HISTOPATHOLOGY; IMMUNOLOGICAL TOLERANCE; IN VIVO STUDY; MALE; MELANOMA; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; RECURRENT CANCER; TUMOR ESCAPE; VESICULAR STOMATITIS VIRUS;

MUS; VESICULAR STOMATITIS VIRUS;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; EPITOPES; GENE EXPRESSION; GENE LIBRARY; GENETIC THERAPY; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; MALE; MELANOMA; MICE; NEOPLASMS; PHENOTYPE; PROSTATIC NEOPLASMS; RECURRENCE; TOPOISOMERASE II INHIBITORS; TUMOR ESCAPE; VESICULAR STOMATITIS INDIANA VIRUS;

EID: 84881310761     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.116     Document Type: Article

References (40)

1. Aguirre-Ghiso, JA (2007). Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 7: 834-846.
2. Goss, PE and Chambers, AF (2010). Does tumour dormancy offer a therapeutic target? Nat Rev Cancer 10: 871-877.
3. Hensel, JA, Flaig, TW and Theodorescu, D (2013). Clinical opportunities and challenges in targeting tumour dormancy. Nat Rev Clin Oncol 10: 41-51.
4. McGowan, PM, Kirstein, JM and Chambers, AF (2009). Micrometastatic disease and metastatic outgrowth: Clinical issues and experimental approaches. Future Oncol 5: 1083-1098.
5. Gerlinger, M, Rowan, AJ, Horswell, S, Larkin, J, Endesfelder, D, Gronroos, E et al. (2012). Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366: 883-892.
6. Marusyk, A, Almendro, V and Polyak, K (2012). Intra-tumour heterogeneity: A looking glass for cancer? Nat Rev Cancer 12: 323-334.
7. Drake, CG, Jaffee, E and Pardoll, DM (2006). Mechanisms of immune evasion by tumors. Adv Immunol 90: 51-81.
8. Kaluza, KM, Thompson, JM, Kottke, TJ, Flynn Gilmer, HC, Knutson, DL and Vile, RG (2012). Adoptive T cell therapy promotes the emergence of genomically altered tumor escape variants. Int J Cancer 131: 844-854.
9. Poschke, I, Mougiakakos, D and Kiessling, R (2011). Camouflage and sabotage: Tumor escape from the immune system. Cancer Immunol Immunother 60: 1161-1171.
10. Gogas, H, Ioannovich, J, Dafni, U, Stavropoulou-Giokas, C, Frangia, K, Tsoutsos, D et al. (2006). Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354: 709-718.
11. Houghton, AN (1994). Cancer antigens: Immune recognition of self and altered self. J Exp Med 180: 1-4.
12. Pardoll, DM (2002). Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2: 227-238.
13. Diaz, RM, Galivo, F, Kottke, T, Wongthida, P, Qiao, J, Thompson, J et al. (2007). Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res 67: 2840-2848.
14. Qiao, J, Kottke, T, Willmon, C, Galivo, F, Wongthida, P, Diaz, RM et al. (2008). Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nat Med 14: 37-44.
15. Wongthida, P, Diaz, RM, Pulido, C, Rommelfanger, D, Galivo, F, Kaluza, K et al. (2011). Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus. Hum Gene Ther 22: 1343-1353.
16. Daniels, GA, Sanchez-Perez, L, Diaz, RM, Kottke, T, Thompson, J, Lai, M et al. (2004). A simple method to cure established tumors by inflammatory killing of normal cells. Nat Biotechnol 22: 1125-1132.
17. Ferrone, S (2004). Immunotherapy dispenses with tumor antigens. Nat Biotechnol 22: 1096-1098.
18. Kottke, T, Pulido, J, Thompson, J, Sanchez-Perez, L, Chong, H, Calderwood, SK et al. (2009). Antitumor immunity can be uncoupled from autoimmunity following heat shock protein 70-mediated inflammatory killing of normal pancreas. Cancer Res 69: 7767-7774.
19. Kottke, T, Sanchez-Perez, L, Diaz, RM, Thompson, J, Chong, H, Harrington, K et al. (2007). Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer. Cancer Res 67: 11970-11979.
20. Sanchez-Perez, L, Kottke, T, Daniels, GA, Diaz, RM, Thompson, J, Pulido, J et al. (2006). Killing of normal melanocytes, combined with heat shock protein 70 and CD40L expression, cures large established melanomas. J Immunol 177: 4168-4177.
21. Sanchez-Perez, L, Kottke, T, Diaz, RM, Ahmed, A, Thompson, J, Chong, H et al. (2005). Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo. Cancer Res 65: 2009-2017.
22. Kottke, T, Errington, F, Pulido, J, Galivo, F, Thompson, J, Wongthida, P et al. (2011). Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nat Med 17: 854-859.
23. Pulido, J, Kottke, T, Thompson, J, Galivo, F, Wongthida, P, Diaz, RM et al. (2012). Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma. Nat Biotechnol 30: 337-343.
24. Alvarez-Breckenridge, C and Chiocca, EA (2011). A viral strategy to ambush tumors. Nat Med 17: 784-785.
25. Avogadri, F and Wolchok, JD (2012). Selecting antigens for cancer vaccines. Nat Biotechnol 30: 328-329.
26. Gold, JS, Ferrone, CR, Guevara-Patiño, JA, Hawkins, WG, Dyall, R, Engelhorn, ME et al. (2003). A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J Immunol 170: 5188-5194.
27. Guevara-Patiño, JA, Turk, MJ, Wolchok, JD and Houghton, AN (2003). Immunity to cancer through immune recognition of altered self: Studies with melanoma. Adv Cancer Res 90: 157-177.
28. Overwijk, WW, Theoret, MR, Finkelstein, SE, Surman, DR, de Jong, LA, Vyth-Dreese, FA et al. (2003). Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 198: 569-580.
29. Kalluri, R and Weinberg, RA (2009). The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420-1428.
30. Nauseef, JT and Henry, MD (2011). Epithelial-to-mesenchymal transition in prostate cancer: Paradigm or puzzle? Nat Rev Urol 8: 428-439.
31. Santisteban, M, Reiman, JM, Asiedu, MK, Behrens, MD, Nassar, A, Kalli, KR et al. (2009). Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res 69: 2887-2895.
32. Liu, LF (1989). DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58: 351-375.
33. Nitiss, JL (2009). Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 9: 338-350.
34. Nguyen, LV, Vanner, R, Dirks, P and Eaves, CJ (2012). Cancer stem cells: An evolving concept. Nat Rev Cancer 12: 133-143.
35. Polyak, K and Weinberg, RA (2009). Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat Rev Cancer 9: 265-273.
36. Ma, Y, Kepp, O, Ghiringhelli, F, Apetoh, L, Aymeric, L, Locher, C et al. (2010). Chemotherapy and radiotherapy: Cryptic anticancer vaccines. Semin Immunol 22: 113-124.
37. Zitvogel, L, Apetoh, L, Ghiringhelli, F, André, F, Tesniere, A and Kroemer, G (2008). The anticancer immune response: Indispensable for therapeutic success? J Clin Invest 118: 1991-2001.
38. Sanchez-Perez, L, Gough, M, Qiao, J, Thanarajasingam, U, Kottke, T, Ahmed, A et al. (2007). Synergy of adoptive T-cell therapy and intratumoral suicide gene therapy is mediated by host NK cells. Gene Ther 14: 998-1009.
39. Vile, RG, Castleden, S, Marshall, J, Camplejohn, R, Upton, C and Chong, H (1997). Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int J Cancer 71: 267-274.
40. Fernandez, M, Porosnicu, M, Markovic, D and Barber, GN (2002). Genetically engineered vesicular stomatitis virus in gene therapy: Application for treatment of malignant disease. J Virol 76: 895-904.